Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers

Michael W. Jann, Yuen Yi Hon, Shahab A. Shamsi, Jack Zheng, Eric A. Awad, Vicky Spratlin

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Study Objective. To investigate the potential drug-drug interaction between lamotrigine, an antiepileptic agent used to treat bipolar disorders, and olanzapine, an atypical antipsychotic drug also used to treat bipolar disorders, both of which are metabolized by the uridine diphosphate glucuronosyltransferase system. Design. Prospective cohort study Setting. University center for clinical research. Subjects. Fourteen nonsmoking, healthy volunteers. Intervention. Subjects received lamotrigine 25 mg/day for 5 days, then 50 mg/day for 10 days to achieve steady-state concentrations. On day 15, blood samples were obtained before and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours after the dose. Lamotrigine 50 mg/day was then given for an additional 3 days. On the next day, lamotrigine 50 mg and olanzapine 5 mg were coadministered. Blood samples were obtained at the same times as before and at 48, 72, and 96 hours after dosing. Measurements and Main Results. Blood samples were assayed for lamotrigine and olanzapine concentrations by means of high-performance liquid chromatography Olanzapine did not significantly affect lamotrigine disposition, as we observed no differences in the area under the concentration-time curve from 0-24 hours or in lamotrigine plasma concentrations at baseline or at 24 hours. For lamotrigine, the mean time to reach maximum concentration was significantly prolonged during olanzapine coadministration (mean ± SD 1.9 ± 1.3 vs 4.0 ± 3.0 hrs, p=0.025), possibly because of the anticholinergic properties associated with olanzapine. Mild sedation was the only adverse effect that occurred during lamotrigine and olanzapine coadministration. Conclusion. Lamotrigine and olanzapine can safely be combined in healthy volunteers at the low doses studied, without a clinically significant interaction. When prescribing high doses of olanzapine and lamotrigine for bipolar disorder, patients must be carefully monitored.

Original languageEnglish (US)
Pages (from-to)627-633
Number of pages7
JournalPharmacotherapy
Volume26
Issue number5 I
DOIs
StatePublished - May 1 2006

Fingerprint

olanzapine
Healthy Volunteers
Pharmacokinetics
Bipolar Disorder
lamotrigine
Glucuronosyltransferase
Uridine Diphosphate

Keywords

  • Antiepileptic
  • Antipsychotic
  • Bipolar disorder
  • Drug-drug interaction
  • Healthy volunteers
  • Lamotrigine
  • Olanzapine
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Jann, M. W., Hon, Y. Y., Shamsi, S. A., Zheng, J., Awad, E. A., & Spratlin, V. (2006). Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. Pharmacotherapy, 26(5 I), 627-633. https://doi.org/10.1592/phco.26.5.627

Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. / Jann, Michael W.; Hon, Yuen Yi; Shamsi, Shahab A.; Zheng, Jack; Awad, Eric A.; Spratlin, Vicky.

In: Pharmacotherapy, Vol. 26, No. 5 I, 01.05.2006, p. 627-633.

Research output: Contribution to journalArticle

Jann, MW, Hon, YY, Shamsi, SA, Zheng, J, Awad, EA & Spratlin, V 2006, 'Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers', Pharmacotherapy, vol. 26, no. 5 I, pp. 627-633. https://doi.org/10.1592/phco.26.5.627
Jann, Michael W. ; Hon, Yuen Yi ; Shamsi, Shahab A. ; Zheng, Jack ; Awad, Eric A. ; Spratlin, Vicky. / Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. In: Pharmacotherapy. 2006 ; Vol. 26, No. 5 I. pp. 627-633.
@article{7ede47e9440d4adb9106994a0ab444be,
title = "Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers",
abstract = "Study Objective. To investigate the potential drug-drug interaction between lamotrigine, an antiepileptic agent used to treat bipolar disorders, and olanzapine, an atypical antipsychotic drug also used to treat bipolar disorders, both of which are metabolized by the uridine diphosphate glucuronosyltransferase system. Design. Prospective cohort study Setting. University center for clinical research. Subjects. Fourteen nonsmoking, healthy volunteers. Intervention. Subjects received lamotrigine 25 mg/day for 5 days, then 50 mg/day for 10 days to achieve steady-state concentrations. On day 15, blood samples were obtained before and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours after the dose. Lamotrigine 50 mg/day was then given for an additional 3 days. On the next day, lamotrigine 50 mg and olanzapine 5 mg were coadministered. Blood samples were obtained at the same times as before and at 48, 72, and 96 hours after dosing. Measurements and Main Results. Blood samples were assayed for lamotrigine and olanzapine concentrations by means of high-performance liquid chromatography Olanzapine did not significantly affect lamotrigine disposition, as we observed no differences in the area under the concentration-time curve from 0-24 hours or in lamotrigine plasma concentrations at baseline or at 24 hours. For lamotrigine, the mean time to reach maximum concentration was significantly prolonged during olanzapine coadministration (mean ± SD 1.9 ± 1.3 vs 4.0 ± 3.0 hrs, p=0.025), possibly because of the anticholinergic properties associated with olanzapine. Mild sedation was the only adverse effect that occurred during lamotrigine and olanzapine coadministration. Conclusion. Lamotrigine and olanzapine can safely be combined in healthy volunteers at the low doses studied, without a clinically significant interaction. When prescribing high doses of olanzapine and lamotrigine for bipolar disorder, patients must be carefully monitored.",
keywords = "Antiepileptic, Antipsychotic, Bipolar disorder, Drug-drug interaction, Healthy volunteers, Lamotrigine, Olanzapine, Pharmacokinetics",
author = "Jann, {Michael W.} and Hon, {Yuen Yi} and Shamsi, {Shahab A.} and Jack Zheng and Awad, {Eric A.} and Vicky Spratlin",
year = "2006",
month = "5",
day = "1",
doi = "10.1592/phco.26.5.627",
language = "English (US)",
volume = "26",
pages = "627--633",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5 I",

}

TY - JOUR

T1 - Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers

AU - Jann, Michael W.

AU - Hon, Yuen Yi

AU - Shamsi, Shahab A.

AU - Zheng, Jack

AU - Awad, Eric A.

AU - Spratlin, Vicky

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Study Objective. To investigate the potential drug-drug interaction between lamotrigine, an antiepileptic agent used to treat bipolar disorders, and olanzapine, an atypical antipsychotic drug also used to treat bipolar disorders, both of which are metabolized by the uridine diphosphate glucuronosyltransferase system. Design. Prospective cohort study Setting. University center for clinical research. Subjects. Fourteen nonsmoking, healthy volunteers. Intervention. Subjects received lamotrigine 25 mg/day for 5 days, then 50 mg/day for 10 days to achieve steady-state concentrations. On day 15, blood samples were obtained before and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours after the dose. Lamotrigine 50 mg/day was then given for an additional 3 days. On the next day, lamotrigine 50 mg and olanzapine 5 mg were coadministered. Blood samples were obtained at the same times as before and at 48, 72, and 96 hours after dosing. Measurements and Main Results. Blood samples were assayed for lamotrigine and olanzapine concentrations by means of high-performance liquid chromatography Olanzapine did not significantly affect lamotrigine disposition, as we observed no differences in the area under the concentration-time curve from 0-24 hours or in lamotrigine plasma concentrations at baseline or at 24 hours. For lamotrigine, the mean time to reach maximum concentration was significantly prolonged during olanzapine coadministration (mean ± SD 1.9 ± 1.3 vs 4.0 ± 3.0 hrs, p=0.025), possibly because of the anticholinergic properties associated with olanzapine. Mild sedation was the only adverse effect that occurred during lamotrigine and olanzapine coadministration. Conclusion. Lamotrigine and olanzapine can safely be combined in healthy volunteers at the low doses studied, without a clinically significant interaction. When prescribing high doses of olanzapine and lamotrigine for bipolar disorder, patients must be carefully monitored.

AB - Study Objective. To investigate the potential drug-drug interaction between lamotrigine, an antiepileptic agent used to treat bipolar disorders, and olanzapine, an atypical antipsychotic drug also used to treat bipolar disorders, both of which are metabolized by the uridine diphosphate glucuronosyltransferase system. Design. Prospective cohort study Setting. University center for clinical research. Subjects. Fourteen nonsmoking, healthy volunteers. Intervention. Subjects received lamotrigine 25 mg/day for 5 days, then 50 mg/day for 10 days to achieve steady-state concentrations. On day 15, blood samples were obtained before and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours after the dose. Lamotrigine 50 mg/day was then given for an additional 3 days. On the next day, lamotrigine 50 mg and olanzapine 5 mg were coadministered. Blood samples were obtained at the same times as before and at 48, 72, and 96 hours after dosing. Measurements and Main Results. Blood samples were assayed for lamotrigine and olanzapine concentrations by means of high-performance liquid chromatography Olanzapine did not significantly affect lamotrigine disposition, as we observed no differences in the area under the concentration-time curve from 0-24 hours or in lamotrigine plasma concentrations at baseline or at 24 hours. For lamotrigine, the mean time to reach maximum concentration was significantly prolonged during olanzapine coadministration (mean ± SD 1.9 ± 1.3 vs 4.0 ± 3.0 hrs, p=0.025), possibly because of the anticholinergic properties associated with olanzapine. Mild sedation was the only adverse effect that occurred during lamotrigine and olanzapine coadministration. Conclusion. Lamotrigine and olanzapine can safely be combined in healthy volunteers at the low doses studied, without a clinically significant interaction. When prescribing high doses of olanzapine and lamotrigine for bipolar disorder, patients must be carefully monitored.

KW - Antiepileptic

KW - Antipsychotic

KW - Bipolar disorder

KW - Drug-drug interaction

KW - Healthy volunteers

KW - Lamotrigine

KW - Olanzapine

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=33646356450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646356450&partnerID=8YFLogxK

U2 - 10.1592/phco.26.5.627

DO - 10.1592/phco.26.5.627

M3 - Article

C2 - 16637792

AN - SCOPUS:33646356450

VL - 26

SP - 627

EP - 633

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5 I

ER -